Countdown to 2021 CBIIC：
President of SHANGHAI KEHUA BIO-ENGINEERING CO., LTD.
Richard Ding is a leader in the diagnostics and life science industry. He was a member of the research team at Myriad Genetics that discovered and developed BRCA, one of the first and most prominent genetic tests. Richard subsequently joined Eli Lilly and took various strategy, business development and operation management roles. In 2006, Richard joined bioMérieux as Senior VP, Strategy and Business Development. In 2014, Richard took the position of President of Asia Pacific at bioMérieux. Richard has recently become CEO of Kehua Bioengineering (KHB), a publicly listed IVD company. Richard is a leader in the emerging personalized medicine field has served on board of director of several life science and diagnostic companies. Richard holds an MBA from the University of Utah and received his undergraduate education at Fudan University, China.